Melior Pharmaceuticals Announces Execution Of License Agreement For Armesocarb By Adhera Therapeutics

Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb). As with all of Melior’s drug candidates, MLR-1019 is a repositioned drug that has demonstrated safety and tolerability in previous clinical studies. Melior has uncovered a previously unreported therapeutic potential of MLR-1019 in PD. As such it represents a new class of PD therapeutic which may be the only drug candidate to address both movement and non-movement aspects of PD. Based upon Melior’s thorough understanding of the drug’s mechanism, an accumulation of a substantial amount of PD animal model data, as well as anecdotes from previous clinical use of the drug, Melior has built confidence in the drug’s utility in benefiting multiple aspects of PD. Under the terms of the license Adhera is underwriting the cost of further MLR-1019 development. Further, upon attaining certain milestones, Adhera will have an option to fully acquire all intellectual property associated with MLR-1019. “We are impressed at the unique potential product profile that armesocarb exhibits and have great hopes for its impact on the Parkinson’s disease community”, said Andrew Kucharchuk, CEO of Adhera Therapeutics. “Adhera has proven to be an agile partner whom we have full confidence with towards progressing the clinical development of armesocarb in Parkinson’s clinical studies” said Andrew Reaume, CEO of Melior Pharmaceuticals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!